Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice.

Int J Biol Macromol · 2021 · PMC8580573 · PMID 34774590

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The p -values are indicated as follows: ns: not significant; * p < 0.05: significant; ** p < 0.01: highly significant. 3 Results 3.1 Preparation and characterization of SARS-CoV-2 rS1 protein In this study, the BacMos system was employed to produce a recombinant SARS-CoV-2 S1 protein for vaccine development.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.